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Summary
Terminallydifferentiated plasma cells and mouse T cellsdo not express major histocompatibility
complex (MHC) class II genes although class II gene expression is observed in pre-B and mature
B cells as well as in activated human T cells. Transient heterokaryons were prepared and analyzed
to investigate the mechanisms of inactivation of MHC class II gene in mouse plasmarytoma
cells and mouse T cells. The endogenous MHC class II genesin both mouse plasmarytoma cells
and mouse T cells can be reactivated by factors present in B cells. This reactivation of class II
gene is also observed by fusion with a human T cell line which expresses MHC class II genes,
but not with a class II negative human T cell line. It appears that the loss of MHC class II
gene expression during the terminal differentiation of B cells or T cell lineage is due to absence
of positive regulatory factor(s) necessary for class II transcription.
j~/j
MHC-encoded class II antigens are heterodimeric cell
surface molecules that present antigens to CD4 posi-
tive lymphocytes and thus play an important role in the regu-
lation of immune responses. The expression of MHC class
II molecules is developmentally regulated, and only limited
cell types normally express class II antigen, primarily APCs
such as macrophages, dendritic cells, and B cells. Class II ex-
pression can be induced on human T cells by mitogens or
antigens (1-3) and on macrophages, fibroblasts, and endothelial
cells by IFN-y (4).
The molecular mechanisms responsible for the regulation
of MHC class II gene expression in B cells have been exten-
sively studied (for review see reference 5) . Many cis regula-
tory elements have been identified, and DNA binding pro-
teins which could potentially be involved in the regulation
of class II gene expression have been characterized. Constitu-
tive expression of class II genes on B cells is lost during ter-
minal differentiation into plasma cells. Consistent with this
idea, fusion between mouse plasmarytoma and humanB cells
resulted in a class II negative hybrid. The extinction of class
II gene expression was thought to have resulted from the pres-
ence of dominant suppressor factors in plasmarytoma cells
(6, 7). A similar suppressive effect was observed in a hybrid
between the class II negative mouse T lymphoma BW5147
and class II positive B cell blasts (8). However, these studies
were carried out using stable lines derived by cell fusion. A
major problem with this approach is the potential to lose
chromosomes during the large number of generations of cell
growth required to obtain the hybrids. To overcome this
problem, the transient heterokaryon assay was introduced (9).
Cell fusion of heterologous cell lines produces transient het-
erokaryons in which the nuclei of the parental cell types re-
main separate but are exposed to diffusible regulatory factors
from the cytoplasm and nucleus of each cell type. This ap-
proach, therefore, provides a direct and immediate assay for
tissue- and stage-specific trans-acting regulatory factor(s).
Studies that used heterokaryons have yielded evidence for the
involvement of positive trans-acting factors in regulation of
cell type-specific expression of variety of genes (9-11). It is
surprising that we show here that a mouse MHC class II
gene can be reactivated in both mouse plasmarytoma and T
cells upon fusion with MHC class II positive cells.
Materials and Methods
Cell Culture.
￿
The mouse plasmarytoma cell line MPC11 and
human T cell line Jurkat were purchased from American Type Cul-
ture Collection (Rockville, MD). Mouse plasmarytoma cell line
P3X63-Ag8.563 was obtained from the hybridoma facility at Yale
Medical School. The mouse plasmarytoma cell line P3U1 and human
B cell line Raji were obtained from Dr. R. Accolla (Istituto di scienze
immunologiche, Rome, Italy). The human T cell line H-9 was a
gift from Dr. N. Ruddle (Yale University) and the mouse T cell
line BW5147 was obtained from Dr. C. Janeway (YaleUniversity).
All cell lines used are maintained in RPMI supplemented with 10%
fetal bovine serum (FBS) and 2 mM glutamine. Mouse spleen cells
were prepared from C57B6/J mice.
Cell Fusion.
￿
For most experiments, 2 x 107 cells of each cell
line were mixed, passed through an 18-gauge syringe needle to
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2 h, the culture medium was aspirated and the plates were washed
with prewarmed serum-free medium . 2 ml ofprewarmed polyeth-
ylene glycol (PEG) 1000 (Koch-Light, Ltd ., Hatfield, UK) (50%
[wt/volt serum-freeDMEM ; pH adjusted to -7.4 by the addition
of 7.5% NaHC03) were added and incubated at 37°C for 90 s.
The plates were then washed gently three times with prewarmed
serum-free medium, and incubated in medium containing 10% FBS
for 2 d . Cytoplasmic RNA was prepared as described before (12) .
RNA Analysis.
￿
RNase protection assays were described previ-
ously (13) . Probe for Eca and actin was described before (13) .
PCR Analysis.
￿
First strandcDNA was synthesized by reverse
transcriptase (Seikagaku America Inc., Rockville, MD) using 10
ng of oligo dT as a primer and 2 p.g of cytoplasmic RNA in 10
mM Tris-HCI (pH 8.3), 50 mM KCl, 1.5 MM MgC12, 0.01%
gelatin, 1 mM DTT, 200 jLM dideoxynucleotides . PCR amplifi-
cation was performed using 10% ofsynthesized first strand cDNA,
5 U of Taq DNA polymerase (Perkin-Elmer Cetus Corp., Nor-
walk, CT) in the reaction condition, as was done for first strand
synthesis. 30 cycles were run for 1 min at 94°C, 1 min at 55°C,
and 3 min at 72°C . The sequences ofoligonucleotide primers used
inPCR amplification are as follows : for sense sequenceCCAGAA-
GTCATGGGCTATCA in the exon 1, and for non-sense sequence
GGCTCCTTGTCGGCGTTCTA in exon 4 .
Results and Discussion
Activation ofMHC Class II Gene Expression in Mouse Plas-
macytoma Cells afterFusion withMHC Class IIPositive Cells. To
distinguish gene expression of the plasmacytoma cell from
the B cell fusion partner, we used cell lines of different spe-
cies. Transient heterokaryons were generated using mouse plas-
macytoma cells MPC11 and the human Raji B cell lympho-
blastoid cell line. When RNA from an unfused, mixed
population of MPC11 plus Raji cells was analyzed with a
mouse MHC class II Ea gene probe, a protected fragment
was not observed (Fig. 1, lane 3) . However, whenRNA ob-
tained from MPC11 x Raji heterokaryons 48 h after fusion
was analyzed, Ea transcripts were clearly present (Fig. 1, lane
4) . Similar results were obtained irrespective of the cell ratio
used in fusion (cell ratio of either 1:5 or 5:1, data not shown) .
To determine whether this reactivation of the MHC class
II gene was restricted to a specific plasmacytoma cell line,
MPC11 cells, we also tested two additionalmouse plasmacy-
toma cell lines, Ag8 and P3U1 . TheEa gene was also reacti-
vated in these cells by fusion with human B lymphoblastoid
cells, although the levels of transcripts varies somewhat be-
tween different cell lines (Fig. 1, lanes 5-8) . The P3U1 plas-
macytoma line was used for the original study by stable cell
hybrids which suggested that P3U1 cells contain a dominant
suppressor factor that inhibits the expression ofMHC class
II gene (6) .
We also used different cell types as partners for the heter-
okaryons to determine whether onlyhumanB cells can com-
plement the activation of the silent mouseMHC class II gene.
Plasmacytoma cells were fused with two different human T
cells lines, H-9 and Jurkat cells, which areMHC class Il posi-
tive and negative, respectively . As shown in Fig . 2, Ea tran-
scripts were detected in RNA from fused MPC11 x H-9
cells but not mixed cells (Fig . 2, lanes 3 and 4) . In contrast,
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Figure 1 .
￿
Activation ofEa gene in plasmacytoma cells, MPC11, after
fusion with humanB lymphoblastoid cells (Raji cells) . (Top)RNase pro-
tection assay using 50 tcg of RNA hybridized with Eat probe. (M and
F) Mixed and fused, respectively . (Arrows) Protected signals. (Bottom) Actin
control . 5 ug ofRNA were hybridized with human actin probe which
also hybridizes mouse actin . Lanes : 1, probe; 2-7 correspond with 3-8
(top) ; 8, tRNA ; 9, mouse actin control ; and 10, human actin control .
Jurkat cells that do not express MHC class II genes cannot
reactivate Eat expression in MPC11 cells upon fusion (Fig .
2, lanes 5 and 6) . Again, the activation of the mouseMHC
class gene which is normally transcriptionally silent in MPC11
cells is likely because of the presence of positive trans-acting
regulatory factors supplied by class II positive cells .
A cell sorting experiment was performed to confirm ifthe
reactivation ofclass 11 gene is restricted to cells fused between
two different cell types and not present in either homotypicfused cells or unfused cells. Fused cells between two different
cell types can be isolated from the parental cells using different
cell surface markers in mouse and human cells such asMHC
class I molecule. RNA from three different populations of
cells, human, mouse, and fused cells between mouse and
human cells, were prepared and analyzed after sorting. Only
heterotypic fused cells express both mouse and human class
II gene (data not shown) .
Activation of the Mouse Ecr Gene in Mouse T Cells after Fu-
sion with Human B and T Cells . Although human T cells
expressMHC class II genes upon activation, mouse T cells
do not express mouse class II genes. To determine whether
theMHC class II gene, Ect, can be reactivated in mouse T
cells, we examined the expression of the Ec t gene after fusion
of the mouse T cell line BW5147 with human B or T cells.
Before fusion, we were unable to detectEa transcripts (Fig.
3, lanes 3 and S) . However, after fusion ofBW5147 cells with
Raji or H-9 cells, accurately initiated transcripts were ob-
served (Fig. 3, lanes 4 and 6) . Again, Jurkat cells that do
not expressMHC class II failed to complement mouse class
II gene expression (Fig. 3, lanes 7 and 8) . Therefore, theMHC
class II gene in mouse T cells is also reactivated by fusion
with cells that express an MHC class II gene.
Reactivation ofEcr Gene Expression by Spleen Cells .
￿
We also
prepared C57/BL6 mouse spleen cells and used them as a
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Figure 2 . Activation of Ect
gene in plasmacytoma cells,
MPC11, by human T cells (H-9
and Jurkat cells) . Assay condition
is the same as described in legend
to Fig. 1 . A20 cells are mouse B
lymphoblastoid cells and 10 Frg of
A20 RNA were used . (Bottom)
Actin control . Lane numbers cor-
respond.
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Figure 3 .
￿
Activation of Ea gene
in mouse T cells, BW5147, by human
B lymphoblastoid cells (Raji cells) and
human T cells (H-9 andJurkat cells) .
Assay condition is the same as de-
scribed in legend to Fig. 1 .
fusion partner for both MPC11 and BW5147 cells to test
whether normal B cells can also reactivateMHC class II ex-
pression in these cells . The Ecx gene in this mouse strain has
a deletion in the promoter and part of this first exon such
that the Eci gene is not expressed (14, 15) . Furthermore, since
the volume of splenic B cells is an order of magnitude smaller
than that of an established B lymphoblastoid cell line (5-7
vs 15-25 /m in diameter), if Ect expression was observed
upon fusion using spleen cells, we could rule out the possi-
bility that a hypothetical plasmacytoma or T cell negative
regulatory factor(s) could be diluted out because of the ap-
proximately twofold difference in size ofthe original cell and
the heterokaryon. Since the fusion efficiency of spleen cells
is lower (4-5 vs . 10-15% determined by staining forMHC
class I molecules) and about60% of the total spleen cell popu-
lation is B cells, we used PCR to detect EcrmRNA which
Figure 4 .
￿
Activation ofEct gene by spleen cells. All lanes contain 10%
of PCR product except A20 and MPC11 x Raji lanes which have 1%
ofPCR product . Lanes for BW5147 cells were exposed seven times longer
than the other lanes .is more sensitive than the RNase protection assay. Indeed,
when RNA prepared from these fusions were analyzed using
the RNase protection assay, we could not detect Ea tran-
script (data not shown) . However, as shown in Fig. 4 both
MPC11 andBW5147 cells express Ecx upon fusion with spleen
cells, although the level of transcripts is considerably lower
than that seen in fusions with Raji cells . Low levels of Ecx
transcripts are detected by PCR in MPC11 cells before fu-
sion which we could not detect by theRNase protection assay.
MouseT cells, however, do not exhibit any transcripts unless
they are fused with spleen cells. It seems therefore that at
least some cell lines derived from the B cell lineage contain
residual Ect transcripts. We believe that the lower level of
transcripts detected in fusions with plasmacytoma and normal
spleen cells is a direct reflection of the small volume of the
spleen cells with which the plasmacytoma cells were fused,
and the reduced efficiency of fusion . We presume that the
reduced level of complementation in these heterokaryons is
a consequence of a suboptimal level of transactivator required
for activation of the class II genes .
It has been suggested that the loss ofMHC class II expres-
sion either in mouse plasmacytoma cells or mouse T cells
is due to the expression of a dominant negative regulatory
factor(s) which represses class II expression in these cells (6) .
Since reexpression ofMHC class II gene occurs in our tran-
sient fusion studies, we believe that the absence ofMHC class
II is caused by the loss of positive regulatory factor(s) upon
differentiation of these cells. The reactivation that we ob-
serve is unlikely to be explained by dilution of a negative factor
since any given heterokaryon should only have the equiva-
lent of a twofold change in volume ; even ifmany cells fuse,
probabilistic arguments state that most heterokaryons will
have similar contribution from each partner. Moreover, reac-
tivation can be obtained by fusion with splenicB cells, which
results in a negligible volume increase. The fact that splenic
B cell complementation is suboptimal is, however, consis-
tent with a possible reduced contribution of positive factors
from splenic B cells compared with the larger B lymphoblas-
toid cells. The reexpression of class II genes has also been
obtained by fusion ofmutant cell lines that are class II nega-
tive including those from Bare LymphocyteSyndrome (BLS)
patients who lackMHC class II expression (10) . In one of
the in vitro mutants (RJ 2.2.5) reactivation has also been
achieved by the stable integration ofmouse genomic sequences
into the genome ofthe mutant cell line after DNA-mediated
gene transfer (16) . Therefore, a trans-acting factor provided
either by the fusion partner or transfected genomic DNA
permits reexpression of the class II genes in the mutants cells .
Gel mobility shift assays might determine whether there
is any difference inDNA binding profile in the class II pro-
moter between class II positive and negative cells . However,
the promoter occupancy in vivo in various class II negative
mutants does not entirely correlate with the pattern ofbinding
found in in vitro gel mobility shift assays (17) . In addition,
in vivo footprinting data shows that most class II negative
mutants have promoters unoccupied by these factors except
for one mutant cell line, RJ 2.2.6, which shows no differ-
ence from class II positive cells (17) . The Ea promoter in
several plasmacytoma cells is not occupied or is only minimally
occupied byDNA binding proteinswhen studied by in vivo
footprinting (Kara, C. J ., and L. H . Glimcher, manuscript
submitted for publication) . We also have observed variable
patterns ofDNA binding for the X box and X2 binding
proteins by comparing different plasmacytoma cell lines with
B cell lines by gel mobility shift assay, but no clear correla-
tion with the absence of expression is seen (Fodor, W.,
C.-H . Chang, andR. A . Flavell, unpublished data) . The tran-
scriptional defect in these cells may therefore not be in the
proteins detectable by this assay.
Our data suggest that the lack of class 11 expression in
both the mutant cell lines and the plasmacytoma cells and
mouseT cells studied here is due to the loss ofpositive regula-
tory factor(s) . One model which is consistent with the data
from both stable hybrids and transient heterokaryons is that
plasmacytoma cells synthesize a repressor of the synthesis of
a trans-acting factor(s) which shuts off the synthesis of posi-
tive regulatory factors . In that case, transient heterokaryons
would contain sufficient positive transcription factors to reac-
tivate the class II gene. If these factors had a long til,, the
repression of their synthesis would not affect the results in
the transient assays. The identification ofthe positive regula-
tory factor(s) that is responsible for the reactivation of class
11 gene in plasmacytoma cells andT cells should give a better
insight into our understanding of the regulation of class II
gene expression .
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